Could rushing a Covid-19 vaccine jeopardise future vaccine trials?

Question

Accepted Answer

Rushing a Covid-19 Vaccine Could Jeopardise Future Vaccine Trials

The premature distribution of a Covid-19 vaccine under emergency use guidelines before its safety and efficacy have been definitively established in large-scale trials poses significant risks. A primary concern highlighted by Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, is that such an action could critically hinder the ability to recruit participants for other ongoing vaccine studies. This potential impact could have a chilling effect on the broader scientific effort to develop multiple safe and effective vaccines against the virus.
Difficulty in Participant Recruitment

A significant danger in prematurely releasing a vaccine is the potential to make it exceedingly difficult, if not impossible, for subsequent vaccine candidates to enroll sufficient numbers of volunteers. Large-scale clinical trials, such as those for candidates from Moderna Inc, Pfizer Inc, and AstraZeneca Plc, are aiming to enlist tens of thousands of participants. Johnson & Johnson has also indicated plans to include 60,000 subjects in its Phase III trial. If a vaccine is made available under emergency authorisation without clear signals of efficacy, individuals may become hesitant to join other trials, fearing potential risks or believing the pandemic is nearing its end.
Concerns Regarding Emergency Use Authorisation

The concept of an Emergency Use Authorisation (EUA) for a vaccine is typically reserved for situations where the known benefits of a product outweigh its potential risks in diagnosing, preventing, or treating serious or life-threatening diseases. While an EUA might be considered appropriate once initial studies demonstrate safety and effectiveness, it precedes the completion of a formal marketing application review by regulatory bodies like the US Food and Drug Administration (FDA). Experts have expressed apprehension about using the EUA mechanism for a vaccine intended for widespread use, distinguishing it from its application in treatments like plasma therapy.
Emphasis on Safety and Efficacy Demonstration

Dr Fauci has underscored the absolute necessity of definitively demonstrating that any vaccine is both safe and effective. The guidance from the FDA, for both full approval and EUA, explicitly requires this demonstration. The urgent need for a vaccine to combat the pandemic, which has claimed over 177,000 lives in the United States and more than 800,000 worldwide, is undeniable. However, experts worry that political pressures might lead to the release of a vaccine before it has undergone the full, rigorous testing process, a pathway that has not historically been used for vaccine approval for broad public use.

Reading history

Hide →

This history is cleared when the page is closed.

Could rushing a Covid-19 vaccine jeopardise future vaccine trials?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends